Bertrand Routy

Bertrand Routy was a co-first author on the landmark Science paper demonstrating that gut microbiome composition determines efficacy of PD-1 checkpoint blockade and that fecal microbiota transplant from responding patients can sensitize resistant tumors in mouse models. He has led pioneering clinical trials testing FMT in melanoma patients resistant to anti-PD-1 therapy, providing first clinical evidence that microbiome modulation can rescue immunotherapy responses. His translational research programs span from mechanistic microbiome studies to clinical interventions. He is recognized as a global leader in cancer microbiome research.